Shilpa Medicare Limited ('SML') has entered into a binding agreement with NXITherapeutics AG based out of Basel, Switzerland for development, supply of a New Chemical Entity (NCE).
SHILPAMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.4 pts more than Nifty Microcap 250 and 1.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Shilpa Medicare has signed a binding agreement with Basel-based biotech NXI Therapeutics AG to develop, manufacture, and supply a novel therapy targeting autoimmune and alloimmune disorders. Under the deal, Shilpa will provide end-to-end CMC development, process scale-up, GMP clinical supply, and long-term commercial manufacturing for the NCE, including support for first-in-human clinical studies. The partnership covers early development through commercialization, positioning Shilpa as a full lifecycle partner. Financial terms are not disclosed, but the agreement includes milestone-linked expansion potential and may extend into a multi-year commercial supply relationship. This is described as Shilpa's third major international development and manufacturing contract in recent months, reinforcing its CDMO and biologics growth track.
Positive for the stock — strengthens Shilpa's CDMO revenue visibility, expands its footprint in the fast-growing autoimmune/immunotherapy segment, and signals rising demand from Western biotech clients. No immediate financial impact since terms are confidential, but long-term upside if the NCE progresses to commercial supply.